Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | — | — |
| FORD, VANESSA L | 1 | 39.0% | +40.1% |
| SCHLIENTZ, NATHAN W | 1 | 41.2% | -19.1% |
| LEE, ANDREW P | 1 | 48.4% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 19d overdue |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1616 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | REDWOOD, CHRISTOPHER EVAN | — | DP | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18034252 | PHARMACEUTICAL PACKAGES COMPRISING POLYPROPYLENE CONTAINERS AND NGF AQUEOUS FORMULATIONS PACKAGED THEREIN | SCHLIENTZ, NATHAN W | 1616 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 19d overdue | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial